Dasatrue 50mg Tablet
Marketer
Cipla Ltd
Salt Composition
Dasatinib (50mg)
Overview Dasatrue 50mg Tablet
Chronic myeloid leukemia (CML) patients who haven't responded to, or can't tolerate, other treatments may find relief with Dasatrue 50mg tablets. This medication can be ingested with or without food, but consistent daily timing maximizes effectiveness. Dosage and frequency are determined by your physician based on your specific needs and may be adjusted. Strictly adhere to your doctor's instructions; incorrect usage or overdosage can lead to severe adverse effects. Therapeutic benefits might not be apparent for weeks or months; discontinue only under medical guidance. Common side effects include nausea, vomiting, abdominal discomfort, and skin rashes. Increased heart rate and blood pressure fluctuations (high or low) are possible and require immediate medical attention. Regular blood pressure monitoring may be necessary. Avoid antacids within two hours of taking Dasatrue. The medication can lower blood cell counts, increasing infection risk; regular blood tests are crucial. Inform your healthcare provider of all other medications you're taking, as interactions are possible. Dasatrue is contraindicated during pregnancy and breastfeeding. Refrain from driving if dizziness or visual disturbances occur.
Uses of Dasatrue 50mg Tablet
Chronic myelogenous leukemia, a type of blood malignancy
Major Benefits of Dasatrue 50mg Tablet:
Administer this medication precisely as your physician directs, adhering to both the prescribed dosage and treatment length. Ingest the 50mg Dasatrue tablet whole; avoid chewing, crushing, or fracturing it. Consumption may coincide with meals or be taken independently, although consistent timing is recommended.
Common Side effects of Dasatrue 50mg Tablet:
- Abdominal pain
- Anemia (low number of red blood cells)
- Breathing problems
- Fatigue
- Fever
- Headache
- Infection
- Low blood platelets
- Musculoskeletal (bone, muscle or joint) pain
- Nausea
- Rash
- Vomiting
How to use Dasatrue 50mg Tablet:
Administer this medication precisely as prescribed by your physician, adhering to the specified dosage and treatment length. Ingest the tablet whole; avoid chewing, crushing, or fracturing it. Dasatrue 50mg Tablets can be consumed with or without food; however, consistent timing is recommended for optimal results.
How Dasatrue 50mg Tablet works:
Oncaspar 50mg tablets are a cancer treatment. Their mechanism involves inhibiting the activity of a faulty protein responsible for triggering cancerous cell proliferation. This action helps to control or impede the growth of cancerous cells.
SAFETY ADVICE
AlcoholCONSULT YOUR DOCTOR
Alcohol consumption alongside Dasatrue 50mg Tablet lacks established safety data. Seek medical advice before combining them.
PregnancyCONSULT YOUR DOCTOR
Using Dasatrue 50mg tablets during pregnancy poses a confirmed risk to the fetus; therefore, it's inadvisable. Exceptions may exist in life-threatening circumstances where a physician deems the potential benefits outweigh the risks. Always seek medical advice.
Breast feedingUNSAFE
Lactation and Dasatrue 50mg tablets are incompatible. Evidence indicates potential infant harm from this medication.
DrivingUNSAFE
Driving ability may be impaired by Dasatrue 50mg Tablet side effects. Exercise caution while driving if you experience dizziness or blurred vision after taking Dasatrue 50mg Tablet.
KidneySAFE IF PRESCRIBED
Use of Dasatrue 50mg Tablets in individuals with kidney impairment appears to pose minimal risk. Current evidence indicates dose modification may be unnecessary, however, physician consultation is recommended.
LiverSAFE IF PRESCRIBED
Patients with liver disease can safely take Dasatrue 50mg tablets without requiring any dosage modification.
What if you forget to take Dasatrue 50mg Tablet :
Omit any missed Dasatrue 50mg Tablet dose and resume your regular medication regimen. Avoid taking a double dose.
Facts to Know About Dasatrue 50mg Tablet
| Label | Value |
|---|---|
| Chemical Type | Pyrimidine and Thiazole Derivatives |
| Developing Habits | No. |
| Type of Therapy | Cancer Therapeutics |
| Actions | Kinase inhibitors targeting tyrosine |







